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I 
 
Resumo 
 
O principal objectivo do trabalho apresentado nesta tese foi desenvolver um sistema de 
silenciamento génico usufruindo da capacidade de nanovectorização e propriedades ópticas das 
nanopartículas de ouro. A ideia baseia-se na construção de uma estrutura de DNA que contém um 
oligonucleotídeo terapêutico com capacidade de formar ligações de hidrogénio Hoogsteen com uma 
cadeia dupla de DNA, produzindo uma hélice tripla de DNA, para além de silenciar o gene de 
interesse. As ligações Hoogsteen, mais instáveis que as Watson-Crick convencionais, permitem 
alcançar temperaturas de melting mais baixas. Esta característica, aliada à capacidade de gerar calor 
através de irradiação com um laser nas nanopartículas de ouro utilizadas, vai permitir a libertação do 
oligonucleotídeo terapêutico e posterior silenciamento do gene de interesse sem aumento significativo 
da temperatura do meio. Assim, a tese apresenta três grandes secções: desenho e formação da 
estrutura de DNA, vectorização e silenciamento da expressão génica; as tarefas envolvidas nas 
diferentes secções foram efectuadas em paralelo. 
O desenho da estrutura obtida teve em consideração a temperatura de melting desejável; 
estabilidade a condições fisiológicas dos nucleótidos formadores da sequência, número de ligações 
Hoogsteen e condições iónicas. Para avaliar a formação desta estrutura foram principalmente 
utilizadas técnicas de espectroscopia: análise de FRET e curvas de melting no ultra-violeta. Ambas as 
abordagens permitiram identificar interacções na presença do oligonucleotídeo terapêutico face à sua 
ausência, que poderão indicar a formação da estrutura. Para além disso, as curvas de melting 
permitiram a determinação da temperatura de libertação deste oligonucleotídeo – 40ºC. A 
funcionalização de DNA em dupla cadeia às nanopartículas de ouro foi conseguida, mas não se 
observaram diferenças na migração electroforética quando os três oligonucleotídeos estavam 
presentes. Contudo, o oligonucleotídeo terapêutico demonstrou capacidade de inibição eficiente da 
expressão génica em ensaios de transcrição e tradução in vitro com uma eficiência até 95% e 60%, 
respectivamente. 
 
 
 
 
Palavras-chave: silenciamento génico; DNA antisense; nanopartículas de ouro; hélices triplas de 
DNA; nanovectorização. 
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Abstract 
 
The main objective of the work presented in this thesis was to develop a gene silencing system by 
taking advantage of the nanovectorization capability and optical properties of gold nanoparticles. The 
idea is based on the construction of a DNA structure containing a therapeutic oligonucleotide with the 
ability to form Hoogsteen hydrogen bonds with double-stranded DNA, producing a DNA triple helix, 
besides silencing the gene of interest. Hoogsteen bonds, more unstable than the conventional 
Watson-Crick bonds, permit the achievement of lower melting temperatures. This attribute, coupled 
with the ability to generate heat by laser irradiation of the gold nanoparticles used, will allow the 
release of the therapeutic oligonucleotide and subsequent gene silencing without significant increase 
in the medium’s temperature. Thus, the thesis comprises three major sections: structure design and 
formation, vectorization, and gene expression silencing; the tasks involved in each of these sections 
were conducted in parallel. 
The design of the obtained structure took into account the desired melting temperature, stability at 
physiological conditions of the sequence-forming nucleotides, the number of Hoogsteen bonds and 
ionic conditions. To evaluate the formation of this structure, spectroscopic techniques were mainly 
used: FRET analysis and ultraviolet melting curves. Both approaches allowed the identification of 
interactions in the presence of therapeutic oligonucleotide compared with its absence, which may 
indicate structure formation. In addition, melting curves allowed the determination of the temperature 
of release of this oligonucleotide – 40ºC. The double-stranded DNA functionalization to gold 
nanoparticles has been achieved, but there was no difference in electrophoretic migration when the 
three oligonucleotides were present. However, the therapeutic oligonucleotide was able to efficiently 
inhibit gene expression in in vitro transcription and translation assays with efficiency up to 95% and 
60% respectively. 
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1. Introduction 
 
The work here presented, although solely focused on gene therapy, is a small part of a larger 
project whose central focus is on nanotheranostics. 
 
1.1. Nanotheranostics 
 
Theranostics is the combination of real-time diagnotics with delivery of medication (Prigodich et al., 
2009; Ho and Leong, 2010; Lukianova-Hleb et al., 2010; Xie et al., 2010) and aims to make a 
treatment shorter, safer and more efficient through selective targeting of specific (diseased) tissues or 
cells. However, the initial phase of the development of theranostics has already revealed two main 
challenges: (i) lack of multifunctional methods and agents; and (ii) deficient selectivity and specificity of 
available agents (Lukianova-Hleb et al., 2010). 
Over the last decade, several multifunctional approaches have been employed as theranostic 
agents, such as: fluorescent dyes, capsule-type sytems (liposomes, micelles, polyelectrolyte and 
polymer capsules) and nanotechnological materials (especially nanoparticles; NPs). Taking advantage 
of the potential of certain materials at the nanometer scale, and hence of nanotechnology, appears to 
be the most advantageous and effective approach for the combination of diagnosis and therapy in a 
single system. Several reports of the use of nanotechnology for application in theranostics 
(nanotheranostics or theranostic nanomedicine) have already been presented (Bagalkot et al., 2007; 
Medarova et al., 2007; Park et al., 2008; Yezhelyev et al., 2008; Prigodich et al., 2009; Ho and Leong, 
2010; Lukianova-Hleb et al., 2010). 
 
1.2. Nanotechnology 
 
Nanotechnology is a multidisciplinary scientific field that involves the study, creation and control of 
matter on the nanometer (one billionth of a meter) scale. 
Since the discovery of their quantum size effects, biomedical applications and methods of 
manufacturing, NPs are one of the most explored and employed class of nanomaterials (Salata, 2004; 
Kotov and Stellacci, 2008). NPs can be composed of one or more inorganic compounds such as noble 
metals, heavy metals, iron, etc. (Niemeyer and Mirkin, 2004). In particular, noble metal NPs have been 
attracting much interest due to their simplicity, versatility, easily tunable physicochemical properties 
and high surface areas which make them suitable for many biological applications (Baptista et al., 
2008; Wilson, 2008). These properties are mainly dependent on their size, shape and composition (Su 
et al., 2003). 
Among noble metal NPs, gold nanoparticles (AuNPs) have been subject of extensive research and, 
in the last years, led to the development of a myriad of techniques and methods for diagnostics, 
imaging, drug delivery and therapeutics (Hu et al., 2006; Baptista et al., 2008; Sperling et al., 2008; 
Boisselier and Astruc, 2009; Huang and El-Sayed, 2010). This widespread use of AuNPs is the 
consequence of two important properties for biomedical application: unique optical properties and 
ease of surface functionalization. 
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1.2.1. Optical properties 
 
One of the most studied properties of AuNPs is their interaction with light. The free surface 
electrons of the AuNP undergo a collective coherent oscillation on its surface when in the presence of 
the electromagnetic waves of the light. At a particular frequency of the light, this process is resonant 
and is termed the localized surface plasmon resonance (LSPR) oscillation (Eustis and El-Sayed, 
2006). The LSPR frequency for spherical AuNPs with diameters between 10-100 nm lies in the visible 
region of the electromagnetic spectrum (Jain et al., 2007) due to the similar quantum confinement of 
the nanoparticle for the oscillating electrons and the incident radiation wavelength (El-Sayed, 2001). 
The LSPR can be tuned by modification of the nanostructure size, shape, composition or the dielectric 
constant of the surrounding medium (Jain et al., 2006; P.K. Jain et al., 2008) in order to suit the 
biomedical application. 
Plasmon oscillations in a NP can either decay by radiating its energy resulting in light scattering, or 
non-radiatively as heat (P.K. Jain et al., 2008). Only the latter mechanism of dissipation is covered 
under the scope of this work. 
 
AuNPs are thought to generate heat by light activation and these heaters are useful for applications 
in biomedicine because temperatures above 37ºC lead to fever and temperatures higher than 42ºC 
are lethal to human cells. The increase in temperature in the vicinity of AuNPs’ surface can be 
explained by the optical near-field effect and that increase is a function of the distance from AuNPs’ 
surface (Govorov et al., 2006; Govorov and Richardson, 2007) as shown in Figure 1.1. 
 
 
Figure 1.1 – A) Scheme of an optically driven spherical nanoparticle. B) Temperature increase for a single 
AuNP as a function of the distance from its center and with water as surrounding medium. εNP and ε0 are 
the dielectric constants of the NP and surrounding medium, respectively; RNP is the NP radius; kNP and k0 are the 
thermal conductivity of the NP and surrounding medium, respectively; and I0 is the light intensity inside the matrix 
(Govorov and Richardson, 2007). 
 
This property has been especially exploited as anti-cancer therapy by the selective laser 
photothermolysis of malignant cells. AuNPs conjugated to ligands that are specific to receptors 
overexpressed on cancer cells can be selectively targeted to cancer cells without significant binding to 
healthy cells (Hu et al., 2006; P.K. Jain et al., 2008; Sperling et al., 2008). Upon irradiation with a laser 
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of frequency overlapping the LSPR absorption maximum, the absorbed light is rapidly converted into 
heat and there is a selective heating and destruction of cancer cells at much lower laser powers than 
those required to destroy healthy cells to which nanoparticles do not bind specifically (P.K. Jain et al., 
2008; Boisselier and Astruc, 2009). 
Photothermal therapy using AuNPs requires much lower laser energies than conventional dyes due 
to AuNPs’ 5-fold higher absorption coefficients, which make them minimally invasive (Chen et al., 
2008; P.K. Jain et al., 2008). While the use of visible light resonant AuNPs can be useful for external 
skin/surface cancer treatments (Huang and El-Sayed, 2010), for tumors within bodily tissue, it 
becomes necessary to use near-infrared light in the biological window (Hu et al., 2006; P.K. Jain et al., 
2008; Boisselier and Astruc, 2009). 
Although photothermolysis is the most common application of nanotechnology for cancer therapy, 
one can use this property to achieve the displacement of therapeutic moieties functionalized to the 
NPs’ surface and achieve a therapeutic action by means of gene silencing (Huschka et al., 2010; 
Poon et al., 2010). 
 
1.2.2. Therapy nanovectorization 
 
Therapeutic vectors may carry drugs, genes and imaging agents into living cells and tissues. Over 
the years, several different vehicles for delivery have been designed based on different nanomaterials, 
such as polymers, dendrimers, liposomes, nanotubes, nanorods, etc (Ghosh et al., 2008). The use of 
nanovectors allows the specific delivery of large amounts of therapeutic agents per targeting 
biorecognition event, constituting a major clinical advantage of this approach. Moreover, nanovectors 
are capable of reducing the clearance time of therapeutic agents and provide protection against 
enzymatic degradation (Ferrari, 2005). AuNPs provide excellent characteristics for nanovectorization 
of drug molecules or large biomolecules (e.g. proteins or nucleic acids) due to their high 
surface/volume ratio and ease of functionalization via conventional and/or simple processes. Also, 
gold is essentially inert and non-toxic (Murphy et al., 2008). 
 
The delivery of therapeutic nucleic acids appears to be very promising. An ideal vector must 
possess the following properties: easy production; ability to express its genetic cargo over a sustained 
period; immunologically inert; tissue/cell-specific; ability to infect dividing and non-diving cells; no size 
limit to the genetic material it can deliver (Somia and Verma, 2000). Hitherto, most gene therapies 
have been based on viral vectors because viruses have the mechanisms to transfer their DNA into 
host cells, making them ideal for delivering external genetic material into tumor cells. However, the 
use of common viral vectors raises cytotoxicity and adverse immune responses in humans (Waehler 
et al., 2007; Boisselier and Astruc, 2009).  
AuNPs can be used as synthetic delivery vectors that have already proven successful in delivering 
large biomolecules such as peptides, proteins, and nucleic acids, and unlike viruses, AuNPs are inert 
to the organism, although less efficient than viral vectors (Ghosh et al., 2008). 
Delivery of DNA by means of AuNPs has been developed first by Rotello’s group using cationic 
ligands (McIntosh et al., 2001) and then with amphiphilic ligands that were more efficient on 
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transfection (Ghosh et al., 2008). Rosi et al. have conjugated AuNPs with negatively-charged 
oligodeoxynucleotides using antisense oligonucleotides (Rosi et al., 2006) and AuNPs conjugated with 
siRNA (Giljohann et al., 2009) for gene therapy. Rotello et al. also reported another approach to gene 
delivery by means of AuNPs-directed photorelease of oligonucleotides where, upon ultraviolet (UV) 
irradiation within the cells, DNA is released from AuNPs resulting in a high level of DNA-transcription 
recovery in vitro, and with significant nuclear localization of the DNA in cells (Han et al., 2006). 
 
In the last years, the use of NPs for photothermal therapy (see section 1.2.1) and/or as suitable 
vehicles to act as vectorization platforms (see section 1.2.2) has raised much interest in the treatment 
and/or prevention of cancer (Cheng et al., 2009; Bardhan et al., 2011; Gianella et al., 2011; Ke et al., 
2011; Melancon et al., 2011). This is due to the enhanced permeability of tumor vasculature and 
cancer markers that facilitate retention of NPs within a tumor coupled with the increasing burden of 
this disease worldwide. 
 
1.3. Cancer therapy 
 
Cancer is among the major causes of mortality in the developed world, and the worldwide 
incidence continues to increase. The mainstay of treatment for cancer is surgery, radiation, 
chemotherapy, antibody-blocking therapy, or a combination of these therapies. These methods are 
invasive (e.g. surgery) and/or hazardous due to lack of selectivity to cancerous cells or tissue (e.g. 
chemotherapy, radiotherapy). Although cancer treatment is improving and extending survival rate for 
people with cancers at many sites, there is a need to reduce the impact of highly toxic agents to 
healthy tissue. Also, the poor bioavailability seriously compromises the therapeutic efficacy of many 
otherwise beneficial drugs (Chen et al., 2008). These treatments also inhibit growth and development 
of blood cell lineages, ultimately leading to increased susceptibilities to secondary infections. 
To surmount at least some of these challenges, alternative non-invasive and selective methods are 
being exploited and developed. In particular, gene therapy is receiving increasing attention and could 
represent an attractive approach for novel treatment and/or prevention of cancer by the controlled 
introduction of therapeutic nucleic acids into target cells in order to block the expression of specific 
genes. Gene expression can be regulated at either the transcriptional or post-transcriptional level. At 
the transcriptional stage, oligonucleotides must enter the nucleus of a cell and specifically bind to the 
RNA polymerase promoter of double-stranded genomic DNA to form triple helices that prevent 
transcription (Tamm et al., 2001; Patil et al., 2005; Rayburn and Zhang, 2008). At the post-
transcriptional level, antisense oligonucleotides and small interfering RNA (siRNA) are available for 
the sequence-specific gene silencing. 
 
1.4. Gene silencing 
 
RNA interference (RNAi) is the phenomenon that triggers degradation of messenger RNA (mRNA) 
complementary to either strand of a short double-stranded RNA (dsRNA; Lewin, 2007). In theory, the 
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RNAi machinery can be exploited to silence nearly any gene, giving it a broad therapeutic potential 
(Whitehead et al., 2009). 
The general mechanism of RNAi is triggered by the presence of long pieces of dsRNA and involves 
the cleavage of these molecules into regulatory molecules of twenty-one to twenty-three bases with 
short (two base) protruding 3’-ends by Dicer. In practice, siRNA can be synthetically produced and 
then directly introduced into the cell, thus circumventing Dicer mechanics. 
Once siRNA is present in the cytoplasm of the cell, it is incorporated into a ribonuclear protein 
complex known as the RNA-induced silencing complex (RISC). Within the RISC complex exists a 
member of the Argonaute protein family (in mammalian cells, the protein is Ago2) which unwinds the 
siRNA. The activated RISC, which contains the antisense strand of the siRNA as a template (the 
sense strand is cleaved), selectively degrades mRNA that is complementary to the antisense strand 
(Hammond et al., 2001; Hannon and Rossi, 2004; Meister and Tuschl, 2004; De Paula et al., 2007; 
Whitehead et al., 2009; Kim et al., 2005). The homologous mRNA, upon binding to RISC, is cleaved 
between bases 10 and 11 relative to the 5′-end. The activated RISC complex can then undergo 
numerous cycles of mRNA cleavage, which further propagates gene silencing (De Paula et al., 2007; 
Whitehead et al., 2009). A schematic representation of the siRNA pathway is depicted in Figure 1.2. 
 
 
Figure 1.2 – The siRNA pathway in mammalian cells (adapted from de Fougerolles et al., 2007). dsRNA is 
cleaved into siRNAs by Dicer. These fragments are then incorporated in RISC, which becomes activated by the 
presence of the antisense strand of the siRNA. This complex is capable of mRNA degradation complementary to 
the antisense strand of siRNA.  
 
Antisense silencing is based on single-stranded oligonucleotide sequences that are specifically 
designed to hybridize to corresponding mRNA and inhibit its function by modulation of splicing or 
disruption of ribosome assembly (Tamm et al., 2001; Patil et al., 2005). Therefore, there is a potential 
role for antisense oligonucleotides in the treatment of disease. 
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Antisense oligonucleotides and siRNA show significant potential in new molecular approaches to 
down-regulate specific gene expression in cancer. However, there are still significant obstacles to be 
overcome before their use as anticancer agents in clinical applications. Naked oligonucleotides show 
extremely short half-lives (seconds to minutes) when delivered into the bloodstream due to renal 
clearance (because of their small size) and to RNase and DNase action. Also, the cellular uptake of 
naked oligonucleotides is limited (Oliveira et al., 2006; Pirollo and Chang, 2008). Therefore, the 
efficiency of these approaches for cancer therapy relies on finding suitable delivery vectors that can be 
systemically administered to reach both primary and metastatic tumor cells. Several different 
vectorization approaches have been developed based on nonviral lipids or protein carriers, including 
cholesterol, liposomes, antibody protomer fusions, cyclodextrin nanoparticles, fusogenic peptides, 
aptamers, biodegradable polylactide copolymers, and polymers (Pirollo and Chang, 2008). Positively 
charged cationic liposomes and polymers, such as polyethyleneimine, are currently the two major 
carriers used to complex with negatively charged oligonucleotides for systemic delivery (Oliveira et al., 
2006; De Paula et al., 2007). 
 
1.5. DNA triple helices 
 
The DNA double strand is formed by two complementary strands, where an adenine (A) pairs with 
thymine (T) and guanine (G) with cytosine (C) forming A•T and G•C base pairs through Watson-Crick 
hydrogen bonds. However, in the DNA major groove, acceptor and donor groups are spatially 
available to form hydrogen bond interactions with a third external strand. The hydrogen bond 
interactions involved in triple-helix formation are a less stable hydrogen-bonding pattern, referred to as 
Hoogsteen hydrogen bonds (Chan and Glazer, 1997; Duca et al., 2008). 
There are several requisites for triplex formation – it occurs when a DNA or RNA oligonucleotide 
binds specifically to the major groove of a homopurine region of DNA. A triplex-forming oligonucleotide 
(TFO) can be categorized in either the pyrimidine or purine motif, depending on its base composition 
and binding orientation relative to its DNA target site. 
A TFO formed by C and T binds parallel to the purine-rich strand of DNA via Hoogsteen bonds in a 
pyrimidine motif. Ts belonging to the third strand bind to A in A:T basepairs and protonated Cs (C+) 
bind to G in G:C+ basepairs. Because the protonation at N3 of C is required for proper Hoogsteen 
bonding with N7 of G, the pyrimidine motifs occur only under acidic conditions (pH < 6). This imposes 
a limitation to the use of pyrimidine oligonucleotides at physiologic pH without further modification 
(Chan and Glazer, 1997; Duca et al., 2008). 
In the purine motif, the TFO consists of As and Gs which bind to the purine-rich strand of DNA by 
A:T, G:C and A:A Hoogsteen hydrogen basepairs. These TFOs bind antiparallel to the purine-rich 
strand in DNA and unlike the pyrimidine motif, the purine motif requires no base protonation and 
exhibits pH independent binding (Chan and Glazer, 1997; Duca et al., 2008). Figure 1.3 shows these 
two motifs and the hydrogen bonds that each one form. 
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Figure 1.3 – Motifs in triplex DNA formation and hydrogen bonding. A) Pyrimidine binding motif. Above: 
binding of a TFO in a parallel orientation to a polypurine strand of DNA; Below: the two canonical base triplets of 
this motif. B) Purine binding motif. Above: binding of a TFO to the polypurine strand of DNA in an antiparallel 
orientation; Below: three canonical base triplets in this motif.  · represent Hoogsteen hydrogen bonds; | represent 
Watson-Crick hydrogen bonds (adapted from Chan and Glazer, 1997). 
 
The affinity to which a TFO binds to a polypurine site depends on the TFO sequence: purine motifs 
must generally be G-rich (>65%) to form stable triplexes; for the pyrimidine motif, a high percentage of 
Cs appears to be destabilizing. The presence of divalent cations such as Mg
2+
, Ca
2+
 and Zn
2+
 stabilize 
both purine and pyrimidine motifs (Chan and Glazer, 1997; Wu et al., 2002). Spermine, spermidine 
and putrescine are naturally occurring polyamines that also improve the stability of triple helices. 
These agents reduce the electrostatic repulsive forces between the negatively charged phosphate 
backbones of the three strands, allowing triplex DNA to form more readily (Chan and Glazer, 1997). 
To overcome the lack of stability, base analogs can be introduced, the sugar moiety modified, as 
well as the backbone or chemical substances, known to enhance the formation of triplex DNA 
(Knauert and Glazer, 2001; Duca et al., 2008; A. Jain et al., 2008), can be used. 
There are many potential applications for TFOs including site-directed mutagenesis, induced 
recombination and transcriptional and post-transcriptional inhibition (Mukherjee and Vasquez, 2011). 
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1.6. Objectives 
 
The work here presented focus on the use of AuNPs as nanovectors for gene silencing. In order to 
achieve the silencing, suitable single-stranded oligonucleotides (ssDNA) and/or siRNA are aimed to 
be entrapped in specifically designed tertiary nucleic acid structures that are further functionalized to 
the AuNPs’ surface. The entrapment will be accomplished by Hoogsteen hydrogen bonds between a 
trapping double helix DNA structure and part of the effector ssDNA and/or siRNA, forming a triple helix 
of DNA. 
The use of a DNA triplex structure will allow for the use of lower laser energies to achieve the 
melting of the effector strand when compared to simple double stranded constructs. The melting 
temperature of the third strand from the entrapment oligonucleotide will be designed in such a way to 
be released at temperatures just above physiological temperature, i.e., the triplex structure should be 
stable enough until laser irradiation, and the laser energy will be low enough to prevent damage in the 
surrounding cells. 
 
In the present work, the delivery of oligonucleotides might be achieved via the release from the 
trapping molecule through spectral interaction (e.g. near-field effect, thermal effect) with/and between 
the AuNPs. The AuNPs conjugated with the triplex structure will be irradiated by a laser, increasing 
the temperature on the surface of the AuNPs. This increase will lead to thermal denaturation of the 
triplex structures conjugated with the AuNP, releasing the entrapped oligonucleotide within the cell. 
The naked oligonucleotide will thereafter achieve the silencing of its target (see Figure 1.4 for a 
schematic representation). 
Towards the completion of the referred objectives, the work was planned in the following 
consecutive tasks: 
 Design of triplex DNA structures in which a domain of the double-stranded DNA (dsDNA) 
chain is capable of entrapping a third-strand effector oligonucleotide. The length of the triple 
helix section will be designed to satisfy the thermal denaturation profiles attained via the near-
field effect of AuNPs; 
 in vitro temperature effect assessment on the release of entrapped oligonucleotides via 
Förster resonance energy transfer (FRET) analysis and UV melting profiles; 
 Optimization of silencing conditions for antisense and siRNA approach; 
 Synthesis of AuNPs and functionalization of the triplex structure onto the AuNPs’ surface; 
 Assessment of release via thermal denaturation and/or target silencing. 
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Figure 1.4 – Schematic representation of the project. 1) Functionalization of the triplex DNA structure to 
AuNPs via thiol group after previous assessment of triplex structure formation entrapping the therapeutic 
oligonucleotide (represented in green); 2) Release of the therapeutic oligonucleotide – laser irradiation of AuNPs 
and consequent thermal denaturation of the third strand; 3) Gene silencing by the released therapeutic 
oligonucleotide. 
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2. Materials and Methods 
 
2.1. General information 
 
All chemicals were purchased from Sigma-Aldrich in the highest purity available and used without 
further purification. All synthetic oligonucleotides were purchased from STAB Vida, Lda. (Portugal) and 
their sequences are shown in Table 2.1. 
 
Table 2.1 – Unmodified and modified DNA oligonucleotides and their melting temperatures (Tm) according 
to the nearest neighbor model. 
Designation Sequence (5’ to 3’) Tm (ºC) Modification Function 
1T17 
GGGGAGGAAGAGAAGAAAGAA 51.7 
 Triplex formation 
1T17_5’thiol_3’FAM 
5’-thiol-(CH2)6 
3’-FAM 
Vectorization 
2T17 
TTCTTTCTTCTCTTCCTCCCC 51.7 
 Triplex formation 
2T17_5’FAM 5’-FAM Triplex formation 
2T17_5’JOE 5’-JOE Vectorization 
3T17 CATGGTATATTTGTTTGTTGTGT
TGGT 
53.5 
 Triplex formation 
3T17_11dT-JOE T11-JOE Triplex formation 
3T17_T7 
TCTCCCTATAGTGAGTCGTATTA
TTGTTTGTTGTGTTGGT 
64.0  
Inhibition of in 
vitro transcription 
3T17_RBS 
CATGGTATATCTCCTTCTTATTG
TTTGTTGTGTTGGT 
61.5  
Inhibition of in 
vitro translation 
MYCreverse 
AGGCAGTTTACATTATGGCTAAA
TC 
53.7  PCR primer 
T7–MYCforward 
TAATACGACTCACTATAGGGAG
AGCTCATTTCTGAAGAGGACTT
GT 
69.0  PCR primer 
Non-TFO 
TAGACGGTGGTGCAAATAGTAA
CGG 
57.8  
Triplex formation 
control 
 
2.2. DNA structure formation and assessment 
 
2.2.1. FRET analysis 
 
T17 structure (vide Figure 3.1) formation was attempted in a binding buffer (10 mM Tris-HCl, pH 
7.6; TE 1x, pH 7.0; or 10 mM sodium phosphate, pH 7.4) with certain concentrations of MgCl2 or 
MnCl2 and/or NaCl and the concentration of each oligonucleotide (1T17, 2T17_5’FAM and 
3T17_11dT-JOE) was set to 1 µM. Two of the oligonucleotides used (2T17_5’FAM and 3T17_11dT-
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JOE) are labeled with one fluorophore each: FAM and JOE, respectively, whose emission and 
absorption spectra and quantum yields are shown in Figure 2.1. 
 
 
Figure 2.1 – Absorption and emission spectra of FAM and JOE. Black lines correspond to FAM and grey lines 
to JOE. Absorption spectra are represented by solid lines normalized to the extinction coefficients (ε) and 
emission spectra are represented by the dashed lines normalized to the fluorescence quantum yields (Φf). 
 
Oligonucleotides were denatured for 10 min at 80ºC followed by gradual cooling to 4ºC at a rate of 
0.1ºC/min. The experiments were performed at 15ºC in order to guarantee that a triplex can be formed 
if the necessary requirements are met. Emission and excitation spectra were measured using a 
fluorescence spectrophotometer Cary Eclipse with Peltier thermostat accessory (Varian, USA). The 
excitation wavelength (λexc) of FAM was set to 490 nm and the emission intensity was scanned 
between 500 and 700 nm. To record the excitation spectra, the emission wavelength (λem) was set to 
640 nm and the intensity between 400 and 650 nm was recorded. The absorption spectra were 
measured using a UV-Vis spectrophotometer Evolution 300 with Peltier thermostat accessory (Thermo 
Scientific, USA). 
 
2.2.2. Melting profile 
 
UV melting curves for T17 structure were recorded in 10 mM Tris-HCl and 10 mM MgCl2 where the 
concentration of each oligonucleotide (1T17, 2T17 and 3T17) was set to 2 μM. The melting curve was 
recorded at 260 nm from 25 to 85ºC at a scan rate of 1ºC/min using a UV-Vis spectrophotometer 
Evolution 300 with Peltier thermostat accessory (Thermo Scientific, USA). 
 
2.3. Synthesis of colloidal AuNPs (adapted from Lee and Meisel, 1982) 
 
AuNPs were prepared by the citrate reduction method previously described. Briefly, 250 mL of 1 
mM HAuCl4 was brought to a boil while stirring in a 500 mL round-bottom flask. While in reflux, 25 mL 
13 
 
of 38.8 mM sodium citrate was quickly added and the mixture was kept refluxing for 15 min with 
continuous stirring. The colloidal solution was left to cool to room temperature and stored in the dark 
until use. AuNPs concentration was determined by the Lambert–Beer law assuming a calculated 
molar absorptivity for the plasmon resonance band maximum of 2.33×108 M
−1
cm
−1
. The average size 
and morphology of the particles were obtained by analysis of transmission electron microscopy (TEM) 
images. 
 
2.4. Synthesis of dsDNA-AuNP conjugates 
 
After resuspension of the thiol-modified oligonucleotide (1T17_5’thiol_3’FAM) in 0.1 M dithiothreitol 
(DTT), one volume was extracted with two volumes of ethyl acetate and the organic phase was 
discarded after centrifuging for 5 minutes at 21,460 g. This procedure was repeated two more times. 
The aqueous phase was further purified through a desalting NAP-5 column (GE Healthcare, USA) 
according to manufacturer’s instructions, using 10 mM phosphate buffer as eluent. The purified 
oligonucleotide was then quantified by UV-visible spectroscopy using the extinction coefficient at 260 
nm provided by the manufacturer and subsequently mixed with its complementary sequence 
(2T17_5’JOE). The mixture was denatured at 70ºC for 10 min and then allowed to hybridize for 15 min 
at room temperature. 
After these steps, several methods of dsDNA conjugation to AuNPs were employed as described 
below. 
 
2.4.1. Incubation of AuNPs and dsDNA (adapted from Sato et al. 2003) 
 
The pre-hybridized dsDNA was mixed with a 15 nM AuNPs solution in a 1:100 (AuNP:dsDNA) 
ratio. After a minimum of 48 hours at room temperature, the functionalized AuNPs were centrifuged at 
21,460 g for 20 min. The supernatant was discarded and the resulting oily pellet was washed twice 
with 10 mM phosphate buffer (pH 8.0) and finally redispersed with the same solution. The final 
concentration of dsDNA-AuNPs conjugates was determined by the Lambert–Beer law assuming a 
calculated molar absorptivity for the plasmon resonance band maximum of 2.33×108 M
−1
cm
−1
. The 
dsDNA-AuNPs conjugates were stored in the dark at 4ºC until further use. 
 
2.4.2. Salt-aging method (adapted from Hurst et al., 2006) 
 
The pre-hybridized dsDNA was mixed with a colloidal solution of AuNPs in a 1:200 (AuNP:dsDNA) 
ratio. The mixture were brought to 10 mM sodium phosphate buffer (pH 8.0) and 0.01% SDS and 
allowed to incubate at room temperature for 20 min. NaCl concentration was increased to 0.05 M 
using 10 mM sodium phosphate buffer (pH 8.0), 1.5 M NaCl and 0.01% SDS, followed by incubation 
at room temperature for 20 min. This process was repeated to reach final concentrations of NaCl of 
0.1 M, 0.2 M and 0.3 M. After 16 hours of incubation at room temperature, the excess of 
oligonucleotides were removed by centrifugation and removal of the supernatant and this process was 
repeated three times. The final pellet was resuspended in 10 mM sodium phosphate buffer (pH 8.0) 
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and 0.1 M NaCl. The final concentration of dsDNA-AuNPs conjugates was determined by the 
Lambert–Beer law assuming a calculated molar absorptivity for the plasmon resonance band 
maximum of 2.33×108 M
−1
cm
−1
. The dsDNA-AuNPs conjugates were stored in the dark at 4ºC until 
further use. 
 
2.5. Determination of dsDNA-AuNPs hybridization efficiency (adapted from Demers et 
al., 2000) 
 
The dsDNA-AuNPs conjugates (final concentration 5 nM) was denatured using sodium hydroxide 
(final concentration of 0.1 M; final pH of 13) in a total volume of 100 μL of 10 mM phosphate buffer (pH 
8.0) and let to incubate for 2 h at room temperature. The calibration curve was generated by preparing 
a sequential dilution of the JOE-modified oligonucleotide (2T17_5’JOE; concentration range: 0.01 – 
0.5 μM) under the same conditions as the samples. 
The samples were then centrifuged at 21,460 g for 20 min and the supernatant was removed to 
measure the fluorescence emission of the sample in a Cary Eclipse with Peltier thermostat accessory 
(Varian, USA). Sample’s fluorescence emission was converted to molar concentrations by 
interpolation from the standard linear calibration curve. 
 
2.6. Quantitation of thiol-modified oligonucleotides loaded on AuNPs (adapted from 
Sato et al., 2003) 
 
Thiol- and FAM-modified oligonucleotides (1T17_5’thiol_3’FAM) were displaced from the AuNPs’ 
surface via addition of DTT (final concentration of 100 mM) or β-mercaptoethanol (final concentration 
of 12 mM) to 5 nM dsDNA-AuNPs conjugates (pellet obtain in the assay described in 2.5) in a total 
volume of 100 μL. Standard solutions were prepared by sequentially diluting (concentration range: 
0.01 – 0.5 μM) the thiol- and FAM-modified oligonucleotide (1T17_5’thiol_3’FAM) under the same 
conditions as the samples. After 48 hours at room temperature, samples were centrifuged at 21,460 g 
for 20 minutes and then, the supernatant was used to quantify the thiol-modified oligonucleotides in 
solution by measuring the fluorescence intensity. Sample’s fluorescence emission was converted to 
molar concentrations by interpolation from the standard linear calibration curve. 
 
2.7. T7-cMYC-fusion fragment amplification by Polymerase Chain Reaction (PCR) 
 
A 252 bp fragment harboring the 23 bp T7 promoter sequence and a 229 bp fragment of the 
human v-myc myelocytomatosis viral oncogene homolog (MYC) gene was PCR amplified from 
pJET1.2 cloning vector (originally with 2974 bp; Fermentas, Vilnius, Lithuania) using the primers T7-
MYCforward and MYCreverse (see Table 2.1 for sequences). 
PCR amplification was performed on a MyCycler Thermocycler (Biorad) in 25 μL using 0.2 μM of 
each primer, 0.2 mM dNTPs, 1 U Taq DNA Polymerase (Fermentas, Vilnius, Lithuania) and 125 ng of 
template DNA, with the following thermal cycling conditions: intial 5 min denaturation at 95ºC, followed 
by 35 amplification cycles of denaturation at 95ºC for 30 s, annealing at 60ºC for 30 s, elongation at 
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72ºC for 30 s, and a final elongation at 72ºC for 5 min. Purification of the PCR products was performed 
by 1% agarose gel electrophoresis followed by excision of the respective gel band. 
 
2.8. Inhibition of in vitro transcription 
 
Standard in vitro transcription was performed in a volume of 50 µL containing in vitro transcription 
buffer, 10 mM of each NTP, 400 ng of the 252 bp DNA template and with 30 U of T7 RNA polymerase 
(Fermentas, Vilnius, Lithuania) according to the manufacturer’s protocol. Reactions were incubated for 
2 h at 37ºC, followed by heat inactivation of enzyme for 15 min at 75ºC. 
To assess the level of inhibition by the naked oligonucleotides (T7 primer and 3T17_T7), different 
concentrations of each nucleotide were added to the transcription mixture. All transcription reactions 
were then evaluated on a 2% agarose gel electrophoresis with GelRed™ (Biotium, USA) 
incorporation. 
Product quantity determination was performed by pixel counting using ImageJ™ imaging software. 
Determination of the degree of inhibition was performed after normalizing to the intensity of the 
positive control (100%) of the in vitro transcription reaction. 
 
2.9. Inhibition of in vitro translation 
 
The pGFP (4235 bp; 5Prime, GmbH, VWR International) encodes the green fluorescent protein 
(GFP) protein used as template for in vitro protein synthesis reactions. The coupled in vitro 
transcription/translation reactions were performed in a Rapid Translation System RTS 100 E. coli HY 
Kit (5Prime, GmbH, VWR International). GFP protein was synthesized for 6 h at 30ºC followed by 
incubation at 4ºC for 24 h for GFP maturation. GFP protein levels were measured using fluorescence 
spectroscopy (λexc = 395 nm, λem = 510 nm). Assessment of 3T17_RBS olignucleotide influence in 
translation was performed by adding 1 μg of GFP vector and crescent concentrations of the inhibitory 
oligonucleotide to the standard reaction mixture. The translation levels were measured as 
fluorescence of GFP. 
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3. Results and Discussion 
 
The project comprises three major sections – Structure Design and Formation, Vectorization, and 
Gene Expression Silencing. Due to their modular nature in the early stages, the three sections were 
developed in parallel in order to avoid possible bottlenecks. The workflow assumed would also allow 
for the assessment of strategies initially adopted for each section and input the information gathered in 
the other sections, for a more efficient integration of acquired knowledge. 
 
3.1. Structure design and formation 
 
3.1.1. Structure design 
 
Several criteria had to be taken into account when designing the aimed DNA structure: 
- desired melting temperature 
- ability of efficient gene silencing 
- stability at physiologic pH and ionic conditions 
 
To release a therapeutic DNA strand in vivo through thermal triggering, it is desirable that the 
structure’s melting temperature is just above physiologic temperature. Considering that the physiologic 
temperature is around 37ºC, the desirable Tm range lays in the 40 to 45ºC interval. Additionally, for an 
efficient gene silencing, oligonucleotide strands typically with 18-25 nucleotides (Dallas and Vlassov, 
2006) are employed. This would limit the sequence to adenines and timines in Watson and Crick base 
pairing since, for instance, a polyA of 25 nucleotides has a Tm of approximately 43ºC at low salt 
conditions (according to the nearest neighbor model). The use of Hoogsteen hydrogen bonds, and 
hence the formation of DNA triple helices, overcomes this issue as these bonds present decreased 
stability when compared with Watson-Crick hydrogen bonds, decreasing release temperature of the 
therapeutic strand. Triplex formation occurs when an oligonucleotide binds specifically to the major 
groove of a homopurine region of DNA. Consequently, one of the dsDNA strands has to be 
homopurinic so Hoogsteen bonds can be formed (Frank-Kamenetskii and Mirkin, 1995; Chan and 
Glazer, 1997; Duca et al., 2008; Rusling et al., 2009; Fox and Brown, 2011). 
 
To achieve gene silencing in vivo, the structure needs to be stable at physiologic conditions prior to 
the therapeutic strand release. Due to their pH-independent binding to DNA, purine motifs of triplex 
DNA are thought to present significant stability under neutral pH (Chan and Glazer, 1997; A. Jain et 
al., 2008). In this case, the TFO will bind in an antiparallel manner to a purine-rich strand of DNA. The 
use of a pyrimidine motif would require the protonation of cytosines at N3 for proper Hoogsteen 
bonding to N7 of guanines and therefore an acidic pH (Chan and Glazer, 1997; Duca et al., 2008), 
non-compatible with physiologic conditions. 
Previous studies suggest that the presence of divalent cations in the medium potentiate the 
formation of DNA triple helices due to a stability increase (Malkov et al., 1993; Sugimoto et al., 2001; 
Wu et al., 2002; Wan et al., 2009). The interaction of metal ions with triplexes seems not only to be 
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dependent on the valence of the countercations, but also on their ionic radii: in the series of Mg
2+
, 
Mn
2+
, Ca
2+
 and Ba
2+
, the stability increases from left to right, which is in agreement with their radii 
(r
Mg
2  = 0.66 Å, rMn2   = 0.80 Å; rCa2   = 0.99 Å, rBa2  = 1.34 Å), suggesting that a smaller radius may 
increase the stability of these structures (Sugimoto et al., 2001). However, Wan et al. concluded that 
transition-metal ions Co
2+
 and Ni
2+
, compared to alkaline-earth metal ions, show superiority in the 
boosting of triplex DNA formation (Wan et al., 2009). They propose that this is the result of the higher 
affinity of transition-metal ions for purine N7 than alkaline-earth metal ions, enhancing the formation of 
Hoogsteen hydrogen bonds. Nonetheless, the use of free transition metals in solution is not 
compatible with physiologic conditions, and thus their use was discarded. 
 
The interaction of Mg
2+
 and/or Na
+
 and triplex DNA has been thoroughly investigated (Debin et al., 
1999; Wan et al., 2009; Lee et al., 2010; Chiou et al., 2011). Mg
2+
 is generally considered an enhancer 
of triplex formation and its main mechanism of stabilization is charge neutralization: triplex DNA has a 
higher charge density than that of either duplex or single stranded DNA and Mg
2+
 binds to the 
phosphate group, reducing the repulsion between the three phosphate frameworks. Mg
2+
 may also 
coordinate with N and O of bases, contributing to triplex conformation (Wan et al., 2009). It has also 
been determined that concentrations above 10 mM do not appear to increase the stability further 
(Sugimoto et al., 2001). Contrary to the Mg
2+
 effect, Na
+
 has been appointed as an inhibitor of the 
triple helix formation. The hindering effect of Na
+
 against forming triple helix DNA can be explained by 
polyelectrolyte effect: a high concentration of Na
+
 lowers the population of Mg
2+
 in the vicinity of DNA, 
lowering the population of triplex DNA (Debin et al., 1999; Lee et al., 2010). Na
+
 also has the ability to 
form undesirable dimers and tetramers, decreasing the efficiency of triplex formation even in the 
absence of Mg
2+
 (Lee et al., 2010). Thus, on one hand, it is known that higher salt concentrations 
increases Tm’s; on the other hand, in order to potentiate the formation of triple helices, the TFO must 
have a length of at least 12-14 nucleotides (Chan and Glazer, 1997), thus a balance between 
structure stability and desired strand release temperature must be found. 
Additionally, the sequence required to form a triplex DNA structure is limited to nucleotides able to 
form Hoogsteen bonds, so a domain of the triplex-forming strand part has to carry the sequence that 
will perform the silencing. In a first stage, and to attempt to confer increased stability, this triplex-
forming strand will only have 10 therapeutic nucleotides (and not the 18-25 required by literature for an 
efficient gene silencing). 
 
Considering the referred limitations, the design chosen for this work is presented in Figure 3.1 and 
further on referred as T17, due to the 17 nucleotides forming Hoogsteen bonds present. These 17 
nucleotides were chosen by taking into consideration the work of Lee and colleagues, where a similar 
sequence was used as the TFO (Lee et al., 2010). The minor differences in sequence only diminish 
the probability for this sequence to form intramolecular structures. 
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Figure 3.1 – Triplex DNA structure with 17 nucleotides forming Hoogsteen hydrogen bonds (T17 
structure). Oligonucleotide designation from the top to bottom: 3T17 (or TFO); 1T17; 2T17. | represents Watson-
Crick hydrogen bonds; • represents Hoogsteen hydrogen bonds; • represents JOE and • represents FAM. The 
fluorophores were only used for FRET assays and in this case the oligonucleotides labeled with JOE and FAM 
are referred as 3T17_11dT-JOE and 2T17_5’FAM, respectively. Every other experiment was carried out without 
fluorophores but the oligonucleotide sequence remained the same. 
 
The structure presented was designed to minimize the formation of other secondary structures that 
might lead to malformed or unpredicted structures that could lead to incorrect analysis. 
 
3.1.2. Structure formation assessment 
 
Various techniques were used in order to identify and characterize the triplex DNA structure 
assembly. Following the characterization methods employed by others in the study of triple helix 
structures (Plum et al., 1990; Scaria and Shafer, 1996; Lee et al., 2010; Schneider et al., 2010; Chiou 
et al., 2011; Reither and Jeltsch, 2011), fluorescence and UV spectroscopy were the mainly selected 
techniques for the study of the T17 construct. 
The formation of the T17 structure was also characterized by polyacrylamide gel electrophoresis 
(PAGE). However, PAGE results were not conclusive and further optimizations to this method have 
yet to be performed (Appendix I). 
 
3.1.2.1. FRET analysis 
 
FRET analysis was chosen as the main technique to assess the formation of the DNA tertiary 
structure and release of the TFO (the therapeutic oligonucleotide) from the double strand core.  
The labeling of the structure was performed as shown in Figure 3.1. Due to the close proximity 
between the two fluorophores, an efficient energy transfer between the donor and acceptor dye should 
produce a clear variation in intensity upon triplex formation, when compared to the double-stranded 
structure and free TFO case. To maximize this effect, the TFO and one strand of the entrapment 
double helix were labeled with suitable fluorophores that form a donor/acceptor pair with high 
theoretical FRET efficiency and the labeling of the double strand with the donor dye was performed at 
the strand that does not interact directly with the TFO, while the TFO was labeled with the acceptor 
dye. With this arrangement, the presence of energy transfer between the fluorophore pair indicates the 
specific spatial proximity of the three oligonucleotides composing the T17 structure, and consequently, 
the formation of the triple helix structure. The theoretical FRET efficiency between the chosen 
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fluorophores (FAM as donor and JOE as acceptor) is approximately 95.8% (see Appendix II) for the 
distance predicted between the two fluorophores upon triple helix formation (Figure 2.1 and Figure 
3.1). Upon melting, the triple helix is disrupted and the TFO is released from the entrapment with 
concomitant alteration of the spectral signal which will transduce into the increase of the donor’s 
fluorescent emission. Control experiments employing a labeled strand with a closely related sequence, 
but incapable of forming a triple helix structure, were performed in order to assess the formation of 
unspecific secondary structures. 
 
Taking the previously described influence of divalent and monovalent cations into account (see 
section 3.1.1), T17 structure formation was attempted in different binding buffers: 10 mM Tris-HCl, pH 
7.6; TE 1x, pH 7.0; 10 mM sodium phosphate, pH 7.4, and discrete concentrations of MgCl2 or MnCl2 
and/or NaCl, and the best conditions were then chosen according to the results. These experiments 
were carried out at 15ºC in order to maximize thermal stability for structure formation, given that the 
ionic requirements are met. Despite the successfulness of the referred buffers in triple helix formation 
in diverse studies, the above ionic conditions were all screened to determine their effect on T17 
structure formation, due to its higher complexity. Sodium phosphate buffer was then excluded as a 
potential binding buffer after some experiments due to formation of a white precipitate at high 
temperature. This precipitate is likely to be magnesium phosphate, which is insoluble in water. 
The experiments run in Tris-HCl (pH 7.6) and TE (pH 7) had comparable results. However, Tris-
HCl was used as the binding buffer of choice for two reasons: its pH is closer to physiological pH and 
also, the presence of EDTA (a powerful chelating agent that binds Mg
2+
 ions with high association 
constant) in TE competes with the triple helix for the magnesium in solution introducing solution 
equilibrium considerations that unnecessarily complicates the analysis. 
 
Figure 3.2 shows the emission spectra of samples in the presence of the three oligonucleotides 
(1T17, 2T17_5’FAM and 3T17_11dT-JOE), in different concentrations of MgCl2 and/or NaCl.  
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Figure 3.2 – Emission spectra (λexc = 490 nm) of structure T17 in 10 mM Tris-HCl (pH 7.6) and different 
concentration of MgCl2 and/or NaCl at 15ºC. Besides a peak at 520 nm, JOE emission at 550 nm is visible in 
every ionic condition tested; this is a result of JOE direct excitation at 490 nm. 
 
Results show the donor emission peak at 520 nm and the emission of JOE (with maximum at 550 
nm), even in the absence of Mg
2+
 and Na
+
. The presence of JOE emission in all the saline conditions 
assayed does not directly indicate triple helix formation, since a strong JOE direct excitation 
component is present when the solution is excited at 490 nm (see Figure 2.1). In the absence of 
stabilizing ions (Mg
2+
) or when JOE is functionalized to a non-TFO oligonucleotide, emission of the 
acceptor is systematically present in the measured emission spectra (see Appendix III, Figure A.2), 
corroborating that the presence of JOE emission does not unequivocally indicate T17 structure 
formation. The decrease of both donor and acceptor emission for the highest salt concentration, when 
compared to the other samples, is due to the quenching effect of chloride, the counterion used for both 
sodium and magnesium salts. 
 
FAM and JOE are both fluorescein derivatives which present strong spectral overlap. On one hand, 
the high overlap between FAM emission and JOE absorption allows for very efficient energy transfer 
yields; on the other hand, the overlapping absorption of both fluorophores (at 490 nm, the absorption 
by FAM is 78000 M
-1
cm
-1
 and by JOE is approximately 28630 M
-1
cm
-1
; Figure 2.1), makes this FRET 
pair a less-than-ideal choice. However, this pair was selected as a consequence of two intrinsic 
limitations of the system:  
1) The triplex structure is to be functionalized onto the AuNPs’ surface in a posterior phase, 
where the melting of the triple helix has to be followed by FRET analysis, in a parallel 
approach as free-DNA studies. Previous results in our group succeeded to demonstrate that 
rhodamine derivative compounds interact irreversibly with the AuNPs’ surface through the 
amine groups. This observation discards the choice of rhodamine-like acceptors that might be 
a better fit for FRET pairs. 
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2) The AuNPs chosen have a plasmon resonance absorption in the 520 nm region, so in order to 
prevent possible intern filter effects due to the nanoparticle presence, the fluorophore choice 
was further limited to fluorescein derivatives. 
Additionally, due to budget constraints it was necessary to choose a FRET pair that suited both the 
free DNA analysis and its posterior utilization in the presence of AuNPs. 
  
The considerable contribution of direct excitation of JOE rendered challenging the splitting of the 
contribution of FRET and direct excitation to the overall measured emission. To overcome this 
problem, excitation spectra were measured instead. An excitation spectrum measures the 
fluorescence intensity at a single emission wavelength, upon scanning of the excitation wavelengths. 
In practical terms, it will give the relative weight of energy transfer and direct excitation at 550 nm 
when compared to the absorption spectrum of the sample. The emission wavelength has to be 
carefully chosen to minimize donor’s emission. It should be noted that due to the strong spectral 
overlap of the two dyes, a complete splitting of both processes is not possible using steady-state 
fluorescence techniques. For a better understanding of the analysis performed and the relevance of 
excitation spectra to this situation refer to Appendix IV, which shows the different outcomes when 
measuring the excitation spectra of samples with different combinations of fluorophores. 
Here, the emission wavelength was set at 640 nm where FAM emission is considerably smaller 
than JOE’s (Figure 2.1). Figure 3.3 shows the comparison between the absorption spectrum of the 
T17 structure-forming oligonucleotides in 10 mM Tris-HCl and excitation spectra at different 
concentrations of MgCl2 and/or NaCl. 
 
 
 
Figure 3.3 – T17 structure formation assessment by comparison between A) absorption spectrum of the 
mixture and B) excitation spectra (λem = 640 nm) at different concentrations of MgCl2 and/or NaCl. In the 
excitation spectra, there is a clear inversion of the peaks in 10 mM MgCl2 and 10 mM MgCl2, 50 mM NaCl which 
might indicate the T17 structure formation. 
 
Results show that saline conditions lead to different fluorescence intensities at 490 nm. According 
to previous studies, high sodium concentration deters the formation of triple helices, and thus, at a 
concentration of 200 mM of NaCl, no triplex formation was expected (Figure 3.3B – orange series). It 
can be seen that at this salt concentration some emission was obtained through excitation at 490 nm 
which is solely due to FAM direct emission. Additionally, measurements where a closely related 
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oligonucleotide that is unable to form triple helices is used yield similar results (Appendix III, Figure 
A.3). For the other salt conditions tested, they all present increased emission at 490 nm excitation. 
This increase is due to energy transfer from FAM present in the double helix motif to the JOE located 
in the TFO strand, indicating the presence of a triple helix structure. Higher yields of triple helix 
formation were attained when 10 mM MgCl2 and 10 mM MgCl2 plus 50 mM NaCl were used. These 
observations are in accordance with previous reports (Lee et al., 2010). Curiously, the presence of 50 
mM NaCl when 10 mM MgCl2 is also present in solution does not evidence destabilization of the 
structure, even though it was expected that this Na
+
 concentration would decrease T17 structure yield. 
Due to the considerable contribution of direct FAM emission in the excitation spectra, only qualitative 
results can be given, and no accurate yields on the T17 structure formation can be obtained. 
The condition chosen to perform further characterization of the T17 structure was 10 mM MgCl2. 
 
Similar ionic conditions were used with MnCl2 as an enhancer for the formation of the construct and 
results comparable to those using MgCl2 were obtained (Figure 3.4). It can be observed that FAM’s 
emission peak diminishes when in the presence of Mn
2+
. However, that decrease in the donor’s 
fluorescence intensity is not accompanied by an increase in the acceptor’s intensity, which would 
demonstrate an energy transfer process. In can also be observed that the emission peak of FAM is 
more intense when NaCl is present in solution and that intensity increases with the increase of NaCl 
concentration. The donor’s intensity peak reaches its maximum intensity in this assay when the 
divalent cation is not present in solution. This is in agreement with the literature (Lee et al., 2010) as 
Na
+
 is an inhibitor of triple helix formation. Due to time constrains, the work with this salt was 
discontinued. 
 
 
 
 
Figure 3.4 – Emission spectra (λexc = 490 nm) of structure T17 in 10 mM Tris-HCl (pH 7.6) and different 
concentration of MnCl2 and/or NaCl at 15ºC. Besides a peak at 520 nm, JOE emission at 550 nm is visible in 
every ionic condition tested; this is a result of JOE direct excitation at 490 nm. These results are comparable to 
those in Figure 3.2. 
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3.1.2.2. Melting profiles 
 
In order to compare the results obtained by FRET to a standard technique in the analysis of the 
nucleic acids structure, UV melting curves were measured. Figure 3.5 shows the melting curves of the 
T17 structure-forming oligonucleotides, the double helix without the TFO, and the double helix 
oligonucleotides with a non-TFO control of triplex formation. 
 
 
Figure 3.5 – Melting profiles followed by absorption at 260 nm in 10 mM Tris-HCl and 10 mM MgCl2. Black 
solid line: T17 structure-forming oligonucleotides (1T17, 2T17 and 3T17); black dotted line: T17 double helix 
(1T17 and 2T17); grey dashed line: T17 double helix (1T17 and 2T17) and non-TFO. The inset highlights the 
transition from triplex structure to double helix and 3T17 oligonucleotide that occurs around 40ºC. 
 
Results show that when the T17 double helix is present, only one sharp transition at approximately 
75ºC is observed. This value is in agreement with the predicted temperature according to the nearest 
neighbor model (circa 81ºC) for this saline condition. When the triple-helix forming oligonucleotide is 
present, a second transition is observed at around 40ºC, indicating the dissociation of a less stable 
structure. Assuming the presence of the triple helix construct, and according to DNA hyperchromicity 
theory, one would expect Hoogsteen hydrogen bonds to be less stable than typical Watson-Crick 
ones, although triple helix formation induces further tighter stacking within the tertiary structure 
domain, decreasing structure absorbance. Moreover, by design only 17 bases forming Hoogsteen 
bonds are predicted versus 21 bases forming Watson-Crick bonds present forming the double-
stranded component. Seventeen bases forming Hoogsteen bonds correspond to 34 hydrogen bonds 
(see Figure 1.3) that are less stable than their Watson-Crick counterparts. These Watson-Crick 
hydrogen bonds are also present in higher number – 52 in total. The overall result should be a more 
subtle transition than the one found in simple double helix dissociation, and at lower temperatures. 
These results are thus in agreement with the dissociation profile expected from a triple-helix structure. 
At the ionic strength used in this assay, the Tm of the triplex transition is around 40ºC which would 
allow the structure to remain fairly stable at physiological conditions (approximately 37ºC). Inside the 
cells, the structure would respond to the mild temperature raise by laser irradiation at considerably 
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lower energies than required to melt a double strand, resulting in less healthy tissue damage. 
Temperature is a function of the distance from the center of the nanoparticle and is related to the 
incident energy of irradiation (Govorov et al., 2006; Govorov and Richardson, 2007). Therefore, 
although the triplex fraction of the structure is more distant from the center of the nanoparticle, the 
temperature increase needed to melt is lower and consequently, the energy and/or time of irradiation 
should be lower than to melt the double strand fraction. 
Also represented in Figure 3.5 is the melting curve of the double helix in T17 structure and a non-
TFO. This control melting curve permits to identify artifacts in the triplex transition due to the possible 
presence of non-specific secondary/tertiary structures. This oligonucleotide is not able in principle to 
form neither triplex nor duplex structures with any of the other two oligonucleotides. The melting curve 
shows, however, from 0 to 45ºC, a profile that coincides with T17 melting curve. But the absorbance 
continues to increase linearly until it reaches roughly 65ºC and after that, a clear sigmoidal fraction of 
the curve appears, regarding dsDNA to ssDNA transition. Control melting curves of each 
oligonucleotide used alone show that the increase in the absorbance until 65ºC is due to 
intramolecular interactions, that are only formed in the absence of more thermodynamically stable 
structures. In the presence of 1T17 and 2T17, 3T17 yields a different melting profile than compared 
when it is the only oligonucleotide in solution. The transition at 40ºC is only observed when all three 
T17 forming oligonucleotides are present. This taken together with the FRET experiment results 
corroborates that, indeed, the transition obtained is due to the release of the TFO strand from its 
duplex scaffold. 
 
3.2. Vectorization 
 
AuNPs were used as vectors to the DNA delivery, as shown in Figure 3.6A. Unfortunately, due to 
time constrains, the first step of the conjugates characterization and development involved exclusively 
the double helix of the T17 structure conjugated with AuNPs as depicted in Figure 3.6B. 
 
 
Figure 3.6 – Scheme of AuNP conjugates. A) AuNP conjugated with the complete T17 structure; B) AuNP 
conjugated with the double strand of T17 structure. For oligonucleotide sequences refer to Figure 3.1. AuNPs are 
functionalized via thiol group of one of the oligonucleotides. For clarity, one structure is represented per AuNP but 
note that AuNPs will be functionalized with more than one DNA structure. 
 
3.2.1. DNA-AuNP conjugates synthesis and characterization 
 
Spherical AuNPs with a diameter of 14 nm were synthesized via the citrate reduction method as 
previously described (Lee and Meisel, 1982). The average size and morphology of the particles was 
determined by TEM – see Appendix V. 
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Previous results showed that when AuNPs are functionalized with single-stranded DNA, and in the 
presence of free complimentary oligonucleotides, only a small fraction of the AuNP-probes hybridize 
with its complementary target. Thus, the functionalization strategy adopted involved direct 
functionalization of previously hybridized dsDNA. Contrary to the functionalization of ssDNA in which 
an optimized protocol to achieve maximum loading is already available in the literature (Hurst et al., 
2006), the best method to directly functionalize dsDNA to AuNPs or the way to obtain a 1:1 
stoichiometry of the strands is not established so far. The AuNPs were functionalized with pre-
hybridized dsDNA, in which only one of the strands is modified with a thiol group at the 5’ end (Figure 
3.6B). Different approaches were followed in order to find the best conditions (Table 3.1). Both 
oligonucleotides (1T17_5’thiol_3’FAM and 2T17_5’JOE) are labeled with a fluorophore at the 5’ or 3’ 
end (see Table 2.1), and the melting curve of the dsDNA should be followed by FRET analysis 
between this pair in order to determine the Tm of the double strand. 
 
Table 3.1 – Summary of the methods attempted for dsDNA functionalization to AuNPs. 
Method 
# 
Capping 
molecule 
Method protocol 
Ratio 
AuNP:dsDNA 
1 
Citrate 
Functionalization adapted from Hurst et al., 2006; salt-
aging process until 0.3 M NaCl. 
1:100 
2 
Incubation of dsDNA with AuNPs for 48 hours (without 
salt addition). 
3 
PEGylation of AuNPs in various concentrations followed 
by dsDNA functionalization to PEG-AuNPs and salt-
aging process until 0.3 M NaCl. 
1:200 
4 Phosphine 
Functionalization adapted from Hurst et al., 2006; salt-
aging process until 0.3 M NaCl. 
5 Citrate 
Functionalization adapted from Hurst et al., 2006; salt-
aging process until 0.2 M NaCl. 
 
Method #1 is an adaptation of the protocol already optimized to ssDNA (Hurst et al., 2006) and led 
to aggregation of the AuNPs. This method involves a salt-aging process where the ionic strength is 
increased gradually with time. This ensures that the charge of the ssDNA backbone is shielded, 
allowing the approximation between ssDNA and AuNPs (negatively charged due to its citrate 
capping). Also, this method includes sonication between salt additions, avoiding unspecific adsorption 
of the oligonucleotides onto the AuNPs’ surface. The salt-induced aggregation that happened when 
using this protocol to conjugate dsDNA occurred probably because, when in double strand, the 
functionalization does not follow the same kinetic rate as ssDNA. The dsDNA is likely to require higher 
salt to achieve stabilization; however, the AuNPs do not and the charge neutralization induced by the 
increase of ionic strength makes them to come closer, leading to aggregation of the AuNPs. 
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Method #2 maintained the mixture red after 48 hours, indicating that AuNPs kept their disperse 
form. The visible absorption maximum of the conjugates was only 2 nm red-shifted from the non-
functionalized AuNPs’ solution, indicating poor functionalization. Indeed, when emission spectra were 
measured, the emission of FAM and JOE were not detected. To determine if the functionalization was 
effective, displacement of the thiol groups binding was performed by adding DTT to the medium as 
described in section 2.6. Fluorescence present in the supernatant indicates that the thiol-modified 
oligonucleotide was functionalized onto the AuNPs’ surface. However, DTT was not able to displace 
every thiol group from the surface of the nanoparticles as the solution still remained red. β-
mercaptoethanol was used instead, yielding better results. Thus, the absence of fluorescence might 
be explained by nonspecific adsorption of DNA to the AuNPs’ surface due to DNA’s negatively 
charged backbone. 
 
In order to prevent nonspecific adsorption, another approach was pursued: addition of polyethylene 
glycol (PEG) to the AuNPs surface (Method #3). PEGs are expected to stabilize the AuNPs – allowing 
for the use of a salt-aging procedure – and to block the nonspecific adsorption of DNA to the AuNPs’ 
surface and interspace the dsDNA molecules. Additionally, the presence of this molecule decreases 
the probability of cross-talk between the fluorophores from different dsDNA molecules. Moreover, this 
molecule would further stabilize the dsDNA-AuNPs and favor the uptake by cells (Liu et al., 2007) 
which will be utterly important when this system is to be applied in vivo. Different concentrations of 
PEG were screened to determine the optimal concentration for the stabilization of AuNPs (favored 
with higher concentrations of PEG) versus loading of oligonucleotides onto the AuNPs’ surface and 
fluorescent signal strength (favored with lower concentrations of PEG). The minimal concentration of 
PEG which maintained the SPR around 520 nm was 0.006 mg/mL (Appendix VI). At lower 
concentrations of PEG, the absorption maximum is red-shifted, indicating aggregation of the 
nanoparticles. Only the PEG-AuNPs conjugates that did not present aggregation were used to the 
dsDNA functionalization. PEG-AuNPs were then functionalized with previously hybridized dsDNA and 
did not suffer aggregation during salt-aging process. This approach turned out to be ineffective – the 
emission spectrum showed no emission of FAM and/or JOE, and additional studies are required to 
assess the AuNPs’ functionalization efficiency. 
 
The change of capping molecule in method #4 would allow following a regular synthesis without the 
concern of aggregation during the salt-aging process because this capping renders assembly and 
disassembly of AuNPs reversible (Han et al., 2008). Despite having assembled during the salt-aging 
process, the synthesis was resumed and the conjugate solution turned red after a brief centrifugation 
and change of the supernatant to a 25% (w/v) phosphine solution. 
The emission spectrum obtained showed emission at 520 nm, indicating the presence of FAM-
labeled oligonucleotide. At room temperature and considering the structure shown in Figure 3.6B, 
JOE’s emission should be observed preferably instead. Surprisingly, a day after synthesis it was not 
possible to detect neither FAM’s emission nor JOE’s emission. Instead, one peak at 585 nm was 
visible which was concluded to correspond to the Raman peak of water. It was observable when the 
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conjugates were analyzed because there is no emission of other molecules and therefore its peak 
became significant in the spectrum. There are two possible explanations for these results: 
1) Immediately after synthesis, the FAM-labeled oligonucleotide was present free in solution or 
with low loading yield, or; 
2) An interaction between phosphine and the fluorophores (both are fluoresceins derivatives) that 
follows a slow kinetics leads to fluorescein degradation. 
The second hypothesis was discarded after measuring the emission of FAM (not bonded to an 
oligonucleotide, i.e., in its free form) in a 25% (w/v) phosphine solution and its fluorescence did not 
quench. However, due to time constrains, this approach had to be abandoned. 
 
Analyzing the previous attempts using citrate as capping agent of the AuNPs, several conclusions 
can be drawn: 
1) The simple addition of dsDNA previously hybridized to a colloidal solution of AuNPs leads to 
poor functionalization and no fluorescence signal could be obtained; 
2) Following the salt-aging process described elsewhere (Hurst et al., 2006) with dsDNA results 
in AuNPs’ aggregation at low salt concentrations. 
Method #5 reached the compromise regarding these two procedures: less functionalization than if 
the synthesis was completed for the ssDNA case, but higher than the simple addition of dsDNA to 
AuNPs; and no aggregation of the AuNPs should be verified. The solution remained red during the 
synthesis and when emission spectra were measured, a peak at approximately 520 nm was detected, 
corresponding to emission of FAM but there was no peak at 550 nm that would correspond to JOE’s 
emission (Figure 3.7). 
 
 
Figure 3.7 – Emission spectrum of the dsDNA-AuNP conjugates measured at an excitation wavelength of 
490 nm and at 20ºC. The peak observed at approximately 520 nm corresponds to emission of FAM and emission 
at 550 nm (corresponding to JOE) is not observable. 
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The lack of emission at 550 nm in Figure 3.7 indicates that no energy transfer occurred. Most likely, 
this was due to the absence of hybridization between the JOE-labeled strand and its FAM-labeled 
counterpart. The theoretical Tm of the two oligonucleotides functionalized onto the AuNPs’ surface 
(1T17_5’thiol_3’FAM and 2T17_5’JOE) is approximately 52ºC, thus, it is unlikely that the absence of 
JOE emission is due to thermal denaturation. Poor double strand functionalization could explain this 
result even though the two oligonucleotides were hybridized previously to conjugation with the 
particles. Another explanation for this observation may be a high yield formation of double stranded 
construct but due to the great proximity between the two fluorophores, the presence of an electron 
transfer or other non-radiative deactivating process may lead to JOE quenching. Since the FAM 
quantum yield is considerably higher than JOE’s (0.95 vs. 0.75), FAM emission would still be 
observed. Thus, to understand which hypothesis is most likely to be correct, evaluation of the 
functionalization effectiveness of thiolated strands and of dsDNA onto AuNPs’ surface was performed 
by two sequential assays: 
1) Assessment of dsDNA functionalization by chemical denaturation of dsDNA with NaOH; 
2) Determination of thiol-functionalized oligonucleotides with β-mercaptoethanol. 
The first test is based on the disruption of the hydrogen bonds between DNA strands by a strong 
alkaline pH (pH = 13), leading to the release of 2T17_5’JOE oligonucleotides from the vicinity of the 
AuNPs. Since this strand is not directly attached to the nanoparticles, after denaturation it stays in the 
supernatant. The measurement of fluorescence intensity of the supernatant allows the quantification of 
the amount of dsDNA present in that concentration of AuNPs and therefore estimate the number of 
dsDNA functionalized to each AuNP. The concentration of 2T17_5’JOE present in the samples was 
0.006 ± 0.001 µM (see Appendix VII for the quantification results) which corresponds to a yield of 
0.5% – Table 3.2. The second test is based on the cleavage of thiol groups from the AuNPs’ surface 
using a reducing agent (DTT or β-mercaptoethanol). Here, β-mercaptoethanol was the reducing agent 
of choice given the previous poor results with DTT. The thiolated oligonucleotide is labeled at the other 
end with a fluorophore (FAM) which allows the quantification of functionalized strands by measuring 
the supernatant fluorescence after oligonucleotide detachment from the AuNPs. The concentration of 
1T17_5’thiol_3’FAM present in the samples was 0.706 ± 0.024 µM (see Appendix VIII for the 
quantification results) and that represents a 70.1% yield – Table 3.2.  
 
Table 3.2 - Quantification of AuNPs’ surface functionalized oligonucleotides. 
 
Oligonucleotides per 
AuNP (ρmol/cm
2
) 
Strands per AuNP Yield (%) 
2T17_5’JOE 0.32 ± 0.05 1 0.5 
1T17_5’thiol_3’FAM 38.2 ± 1.3 140.2 70.1 
 
Poor functionalization in double strand is therefore the cause of the lack of JOE’s emission in 
Figure 3.7. With 1 strand of JOE-labeled oligonucleotide to 140 strands of FAM-labeled 
oligonucleotide per AuNP, and taking into account the higher quantum yield of FAM, JOE’s emission 
could not be perceived in the emission spectrum. Considering that the oligonucleotides were 
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hybridized prior to functionalization with the particles, this stoichiometry should be approximately 1:1. 
This disparity could have been caused by sonication during synthesis. Ultrasounds in aqueous 
solution generate cavitation bubbles and these can cause damage to nucleic acids by means of 
mechanical or thermal degradation (Elsner and Lindblad, 1989; Larguinho et al., 2010). Although 
fragmentation of DNA is not a concern in this case because its length is not long enough to be cleaved 
by this process, thermal degradation destroys dsDNA. Despite staying in solution, the denatured 
oligonucleotides might not be able to re-hybridize with the tiolated complementary DNA bound to the 
AuNPs due to steric hindrance because more thiolated oligonucleotides are loaded in the meantime. 
To avoid this issue, sonication should be circumvented. Also, both oligonucleotides should be thiolated 
in order to potentiate the stabilization of dsDNA conjugated with the AuNPs and attain a stoichiometry 
closer to 1:1. 
 
Despite this disparity which impairs the determination of the dsDNA-AuNPs’ Tm by FRET melting 
analysis, this parameter was determined in a two-step assay: 
1) Chemical denaturation profile of the double helix from the dsDNA-AuNP conjugates with 
NaOH through increments of pH; 
2) Determination of Tm of the dsDNA without the AuNPs by absorbance at 260 nm in the same 
ionic conditions (10 mM sodium phosphate buffer, pH 8.0). 
The melting curves were then overlapped to associate a pH to a temperature and determine the Tm 
in these conditions and the results are represented in Figure 3.8. 
 
 
Figure 3.8 – Double helix of T17 structure conjugated to AuNPs melting temperature determination by the 
area of fluorescence intensity spectra of 2T17_5’JOE at increasing pH (grey dots) and by absorbance at 
260 nm of the double helix (black line) in 10 mM sodium phosphate buffer (pH 8.0). The Tm according to the 
UV melting curve is approximately 44ºC which corresponds to a pH around 11.3. 
 
The melting transition of dsDNA-AuNPs is around pH 11.3 which corresponds to a temperature of 
roughly 44ºC. This temperature is lower than the previously determined but one has to bear in mind 
that no salt was present in both samples and that decreases the stability, the energy required to 
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disrupt the hydrogen bonds is inferior and thus transitions occur at lower temperatures. And it is 
actually in agreement with the theoretical Tm at this salt condition (approximately 40ºC according to the 
nearest neighbor method). It would be valuable to repeat this assay in T17 structure formation 
conditions in order to have a more reliable analysis for the fully operational system. 
 
3.2.2. Triple stranded DNA (tsDNA)-AuNPs formation assessment 
 
Gel electrophoresis has proved effective in the differentiation between ssDNA-AuNPs and dsDNA-
AuNPs (Pellegrino et al., 2007) based on surface charge of AuNPs. Following the same principle, 
tsDNA-AuNPs should migrate less that dsDNA-AuNPs due to its higher total molecular weight. 
Three samples with a concentration of 25 nM were prepared in 10 mM Tris-HCl (pH 7.6) and 10 
mM MgCl2: ssDNA-AuNP, dsDNA-AuNPs and tsDNA-AuNPs. The first was obtained by denaturing the 
dsDNA-AuNPs with NaOH and discard of the supernatant; and the third one was obtained by 
hybridizing 3T17 oligonucleotide with dsDNA-AuNPs. The conjugates’ stability in these conditions was 
previously tested with positive results. The resulting gel did not show a different migration pattern for 
any of the conjugates (Figure 3.9). This can be easily explained by the ineffectiveness to form high 
yield dsDNA-AuNPs conjugates as already demonstrated in Table 3.2. Nonetheless, the lack of 
differential migration between dsDNA-AuNPs and tsDNA-AuNPs is the result of poor Hoogsteen 
hydrogen bonds formation. This might have occurred due to the high yield loading of AuNPs with 
ssDNA, preventing the approximation of 3T17 oligonucleotide. 
 
 
Figure 3.9 – Electrophoretic analysis of conjugates in 1% agarose. Conditions: 2 hours at 6 V/cm in 1x TBE 
buffer. Lanes: 1- ssDNA-AuNPs; 2- dsDNA-AuNPs; 3- tsDNA-AuNPs. The lack of differential migration denotes 
the lack of functionalization both in dsDNA and tsDNA of AuNPs. If AuNPs were functionalized with dsDNA and 
tsDNA in lanes 2 and 3 respectively, lane 1 should show the fastest migration due to lower surface charge and 
lane 3 the slowest due to high surface charge. 
 
3.2.3. Theoretical calculation of laser intensity to triple strand delivery from AuNPs 
 
Although not fully developed yet, this system of vectorization will in principle allow specific 
delivering of the third strand (3T17 oligonucleotide) due to the capability of AuNPs to generate heat 
upon irradiation with a laser of frequency overlapping the SPR peak (Sperling et al., 2008). Lasers 
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with a frequency of 532 nm are the most common for applications with metal nanoparticles so that is 
the frequency used to calculate the laser intensity. The temperature increase is a function of the 
distance from AuNPs’ surface (Govorov et al., 2006; Govorov and Richardson, 2007) and therefore is 
necessary to take that factor into account – in this case the distance is of circa 8.3 nm to the end of 
the Hoogsteen bonds formed by 3T17 oligonucleotide. The temperature increase required to release 
the third strand is 3ºC, considering that the Tm obtained by UV melting curve (40ºC) is accurate and 
the physiologic temperature is 37ºC. 
According to Govorov and colleagues (Govorov et al., 2006; Govorov and Richardson, 2007), the 
intensity of the laser had to be at least 3.0x10
5
 W/cm
2 
(see Appendix IX for the complete calculation). 
 
3.3. Silencing gene expression 
 
The final objective proposed for this work was to achieve an efficient silencing of a malignant gene 
by means of inhibiting its transcription or, and preferably, its translation into a protein. 
 
3.3.1. Inhibition of in vitro transcription via antisense DNA 
 
Due to simplicity of the process, inhibition of in vitro transcription was attempted first using two 
antisense oligonucleotides (antisense T7 and 3T17_T7; vide Table 2.1 for sequences):   antisense T7 
consists of 23 nucleotides complementary to those of the sense strand of the promoter region 
recognized by T7 RNA Polymerase; and 3T17_T7 is an oligonucleotide containing the 17 triplex 
forming nucleotides of the T17 structure at downstream and the antisense of the T7 promoter at 
upstream. For a more comprehensive view, see Figure 3.10. 
 
 
Figure 3.10 – Strategy for silencing gene expression using antisense oligonucleotides. A) Using an 
oligonucleotide 100% complementary to the sense strand of T7 promoter region (antisense T7). B) Using an 
oligonucleotide with a TFO at downstream and 23 nucleotides complementary to the sense strand of T7 promoter 
(3T17_T7). 
 
The T7 promoter antisense oligonucleotide has already proved to successfully inhibit the in vitro 
transcription (Conde et al., 2010). As proof of concept, a fragment of MYC was used as template for 
inhibition. The protein encoded by this gene is a nuclear phosphoprotein (Kato and Dang, 1992). MYC 
does not act solely as a classic transcription factor as it can also globally influence chromatin structure 
and affect genetic programs, namely cell cycle progression, apoptosis and differentiation. Mutations, 
overexpression, chromosomal translocation and gene amplification of this gene were shown to 
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promote a spectrum of malignancies, including tumors, leukemias and lymphomas (Wasylishen and 
Penn, 2010). 
In an attempt to simulate what would happen when the system of antisense delivery was applied to 
cells, a simplified system was tested where increasing concentrations of the inhibiting oligonucleotide 
were added to a fixed concentration of template DNA without previous hybridization of both 
sequences. Figure 3.11 shows the comparison between the effectiveness of oligonucleotides 
antisense T7 and 3T17_T7 to block the transcription machinery by hindrance of the promoter site. 
 
Figure 3.11 – Inhibition of in vitro transcription via antisense oligonucleotides. A) Agarose gel 
electrophoresis of in vitro transcription reactions in the presence of increasing 3T17_T7 oligonucleotide 
concentration. The represented bands correspond to the mRNA product produced by in vitro transcription. B) 
Transcription levels as function of increasing concentration of the inhibitory oligonucleotide (antisense T7 or 
3T17_T7). Determination of the degree of inhibition was performed after normalizing to the intensity of the positive 
control (100%) of the in vitro transcription reaction. DNA template band was used as internal standard to minimize 
illumination and gel loading heterogeneities. 
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As it can be observed, increasing antisense oligonucleotide concentration leads to a decrease in 
transcription product up to approximately 10% of its native levels. Antisense T7 oligonucleotide was 
proven more effective in inhibiting in vitro transcription than 3T17_T7 oligonucleotide (Figure 3.11B). 
This was the expected result considering that antisense T7 is 100% complementary to the T7 
promoter region and 3T17_T7 has a non-complementary portion (TFO portion) that possibly 
destabilizes the hybridization with the promoter. Nonetheless, 3T17_T7 is clearly able to prevent 
enzymatic activity (Figure 3.11A) with comparable efficiencies. The concentration of DNA template in 
each transcription reaction was of approximately 3 µM. It was thus expected that at least a 3 µM 
concentration or, most likely, an excess of inhibitory oligonucleotide would be needed to completely 
suppress in vitro transcription. When 3 µM of antisense T7 or 3T17_T7 is added, the percentage of 
transcription is of only 13% and 37% respectively and 3% and 5% respectively with 5 µM of inhibitory 
oligonucleotide in the medium (Figure 3.11B). The T7 RNA polymerase is highly specific for its 
individual promoter sequence and transcription will only occur in DNA sequences harboring the T7 
promoter region (Rong et al., 1998; Durniak et al., 2008). Hybridization of these inhibitory 
oligonucleotides to the promoter sequence hinders this region, impairing the recognition by the 
polymerase and consequently, the transcription of the downstream sequence. 
 
Besides lowering the level of in vitro transcription, the addition of these oligonucleotides in the 
reaction had an additional effect: several bands with lower molecular weights than the mRNA product 
are also visible in the gel (see Appendix X, Figure A.10). When transcription begins, i.e. when the 
polymerase recognizes its promoter, it unwinds the template DNA due to its helicase activity (Yin and 
Steitz, 2002; Yin and Steitz, 2004) and the inhibitory oligonucleotide might hybridize with its 
complementary sequence, which could cause the polymerase to halt transcription and therefore, 
produce shorter fragments of RNA. In order to evaluate the likelihood of this, transcription reactions 
where the inhibitory oligonucleotide and template DNA were previously hybridized were performed. 
This experiment would eliminate the vast majority of the abortive transcriptions although not 
completely due to the higher thermodynamic favorability towards hybridizing both strands of the DNA 
template and expel the oligonucleotide from the sense DNA strand. Indeed, the intensity of those 
bands at low molecular weight decreased for both oligonucleotides (see Appendix X, Figure A.11) 
supporting the previously described mechanism. What is more, the intensity of these bands when 
using the antisense T7 oligonucleotide decreased to a further extent than with the 3T17_T7 
oligonucleotide which is also comprehensive due to the increased instability of the hybridization 
between the sense DNA strand and this oligonucleotide due to the TFO portion of the sequence. 
 
Although effective in inhibiting the expression of a gene in vitro, this mechanism of silencing is not 
ideal. Transcription occurs inside the nucleus of cells and thus the inhibitory oligonucleotides – to be 
delivered in the cytoplasm – would have to translocate to the nucleus to perform the inhibition, 
enhancing the difficulty of the system and lessening the chances of significant gene repression. 
The inhibition of gene expression at the post-transcriptional level bypasses this barrier, turning 
itself as more feasible and less intricate.  
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3.3.2. Inhibition of in vitro translation via antisense DNA 
 
To suppress in vitro translation, an antisense oligonucleotide complementary to the Shine-Dalgarno 
sequence (i.e. the ribosome binding site – RBS) and to the start codon was used, – 3T17_RBS (see 
Table 2.1 for sequence) – accomplishing inhibition by hindrance of both ribosome access and initiation 
of translation. This oligonucleotide has also the same TFO sequence as 3T17_T7 used for inhibition of 
in vitro transcription that will not contribute to the inhibition. 3T17_RBS is actually an extension of the 
3T17 oligonucleotide: 3T17 has only 10 nucleotides complementary to the RBS in order to increase 
T17 structure stability whereas 3T17_RBS has additional 10 nucleotides. This oligonucleotide contains 
the complete RBS antisense sequence (20 nucleotides) plus the TFO sequence (17 nucleotides). The 
system used to assess inhibition by 3T17_RBS oligonucleotide was a plasmid with the gene encoding 
GFP and E. coli lysate for conjugation of the plasmid in order to have every component of a cell’s 
machinery. The percentage of translation was determined as a function of fluorescence emission by 
GFP after incubation with discrete concentrations of 3T17_RBS (Figure 3.12). 
 
 
Figure 3.12 – Inhibition of in vitro translation. In vitro translation levels measured as fluorescence of GFP after 
incubation with discrete concentrations of 3T17_RBS. Error bars correspond to average and standard deviation of 
three assays. Red line corresponds to the trend line of the results discarding the 0 μM point. 
 
Fluorescence measured from GFP decreased by about 60% after incubation with 10 µM of 
3T17_RBS. There is a clear correlation between the concentration of inhibitory oligonucleotide used in 
the assay, and the decrease of emission from GFP and therefore, diminution of translation. However, 
even at high concentrations of 3T17_RBS (10 µM), in vitro translation was not fully blocked as in the in 
vitro transcription assay with lower oligonucleotide concentration (5 µM). This might be due to the 
DNases and RNases present in the E. coli lysate that are possibly causing degradation of a 
percentage of the naked oligonucleotide in the assay. Nonspecific nucleases quickly digest unmodified 
oligonucleotides in most biological fluids, rendering them less effective (Galderisi et al., 1999). 
Degradation did not occur in in vitro transcription assays because it was done with purified PCR 
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product, dampening significantly the amount of nucleases present in the medium. If in vitro 
transcription was followed by the same system, it would have perhaps been less effective in silencing 
expression than it was in a more innocuous system. It is important to note, however, that the final 
system of silencing includes functionalization of a DNA construct to AuNPs. The protection against 
nuclease digestion of nucleic acids functionalized onto AuNPs’ surface has already been verified (Rosi 
et al., 2006; Conde et al., 2010; Prigodich et al., 2011) supporting the use of AuNPs as vectors to 
attain a high yield silencing of gene expression. Achieving gene silencing by the use of antisense 
oligonucleotides directly conjugated with AuNPs has been previously reported (Rosi et al., 2006; 
Conde et al., 2010) with positive results. 
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4. Conclusion 
 
The present work describes the development of a gene silencing system in which a triplex DNA 
structure containing a therapeutic oligonucleotide stabilized by Hoogsteen hydrogen bonds is 
functionalized onto the AuNPs’ surface. The therapeutic oligonucleotide is to be released from the 
AuNPs upon increase in the temperature by laser irradiation. In its free form, the therapeutic 
oligonucleotide will be able to silence the expression of a gene of interest. The three main parts of this 
project (structure formation, AuNP vectorization, and gene silencing) were assessed in parallel and 
several conclusions can be drawn considering the obtained results. 
 
The first task was to build a complex structure of DNA (named T17 structure) that was composed 
by a double stranded portion and a therapeutic oligonucleotide to be released by thermal denaturation. 
This third oligonucleotide was bond to one of the strands of the dsDNA by Hoogsteen base pairing 
that would allow the release at lower temperatures that the conventional Watson-Crick base pairing. 
The formation of T17 structure was attempted in physiological pH (7.6 in 10 mM Tris-HCl) and 
different concentrations of MgCl2 and/or NaCl. Other divalent cations were also screened although an 
extensive analysis was not performed. The assessment of T17 structure formation was performed 
mainly by fluorescence spectroscopy (FRET analysis) and UV melting profiles. In order to follow the 
construction by FRET, labeling of two out of the three oligonucleotides was performed with two 
fluorescein derivatives (FAM and JOE). Emission spectra revealed direct excitation of the acceptor 
fluorophore rendering the analysis inconclusive. To circumvent this issue, an analysis using excitation 
spectra instead was employed. The measured spectra revealed that when two conditions seemed to 
reveal the T17 structure assemble: 10 mM MgCl2 and 10 mM MgCl2 50 mM NaCl. Changing of the 
fluorophores to suppress the direct excitation would lead to a more straightforward analysis. 
Following absorption at 260 nm changes with the gradual increase of temperature also revealed 
that T17 might have formed when 10 mM MgCl2 is present in the medium since two transitions were 
observed. 
 
AuNPs were the vector of choice to functionalize the T17 construct. At first, double stranded 
functionalization to AuNPs was attempted via conjugation with the thiol group of one of the strands. 
Several methods of functionalization of dsDNA onto the AuNPs’ surface were tested in order to find 
the best conditions of conjugation since an optimized method for dsDNA functionalization to AuNPs is 
not yet well established. The best results were attained by adapting the protocol described by Hurst 
and colleagues (Hurst et al., 2006) but functionalization in dsDNA was still poor. To overcome this, 
three strategies could be employed: 
1) Thiolate both strands in order to avoid removal of the indirectly functionalized oligonucleotide 
upon salt addition and temperature denaturation caused by sonication; 
2) Avoid sonication during synthesis of dsDNA-AuNP conjugates; 
3) Or functionalize only the thiolated strand and instead of having a three-stranded construct, 
create a double helix paired only by Hoogsteen hydrogen bonds. 
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The last hypothesis would also decrease the steric hindrance at the AuNPs surface. 
 
The final main task was the silencing in vitro transcription and in vitro translation by an antisense 
oligonucleotide strategy. In the present work is demonstrated that oligonucleotides not fully 
complementary to the target sequence (T7 promoter for in vitro transcription and RBS and start codon 
for in vitro translation) were able to silence these cellular processes. 
The full system remains to be tested and fully developed. Nonetheless, these results prove the 
feasibility of these oligonucleotides to significant block transcription and translation machinery in its 
naked form in a nuclease-rich medium (in the case of inhibition of in vitro translation) so they will have 
an even higher yield of blockage when protected by AuNPs. 
 
Many milestones have been accomplished given the little time available but, undoubtedly, there are 
still many obstacles to be overcome in order to achieve the planned system of delivery. However, 
much light has been shed regarding the formation of triplex DNA and its stability under physiological 
conditions. Perhaps base analogs or stabilizing molecules compatible with physiologic conditions 
should be used as an aid to form more stable structures without compromising the release of the TFO 
by a mild raise of temperature. 
 
Many questions are yet to be answered, e.g.: 
- Is the structure really being formed? 
- Is it better to have two oligonucleotides stabilized by Hoogsteen hydrogen bonds (1T17 and 
3T17 oligonucleotides) rather than the T17 structure? 
- What is the best way to achieve a high yield loading of dsDNA onto AuNPs? 
- Is it possible to follow the same functionalization protocol to load tsDNA or this structure is too 
unstable to cope with the high NaCl concentrations? 
These questions will hopefully be answered in future projects until the system is fully operational. It 
is important to stress that the envisioned system can in principle be applied to a plethora of other 
targets for minimally invasive nanomedical purposes. 
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6. Appendices 
 
 
Appendix I – PAGE analysis 
 
 
 
Figure A.1 – 12% non‐denaturing PAGE in 17.8 mM Tris-borate (pH 7.2) and 10 mM MgCl2. Lanes: 1 – 1T17 
+ 2T17; 2 – T17 structure (1T17 + 2T17 + 3T17); 3 – 1T17 + 2T17 + non-TFO. For the sequences of these 
oligonucleotides refer to Table 2.1 in the Material and Methods section. PAGE was run at 70 V at 4ºC for 2 hours 
and 30 minutes. The gel was then stained with ethidium bromide. The gel should had be run for a longer time in 
order to understand if lane 2 shows two gel bands (and therefore evidences the presence of the T17 structure as 
well as the presence of the double helix) or only one broader gel band, corresponding to the double helix formed 
by 1T17 and 2T17 oligonucleotides. 
 
 
 
  
  1        2        3 
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Appendix II – FRET efficiency calculation 
 
The FRET efficiency (E) is the fraction of photons absorbed by the donor which are then 
transferred to the acceptor. This fraction can be given by the following equation: 
 
E  
1
1  (
r
R0
)
6              Equation 1 
   
where R0 is the Förster distance (distance at which energy transfer efficiency is 50% between the 
donor and acceptor) and r is the donor-acceptor distance. As the distance between donor and 
acceptor decreases, the FRET efficiency increases. 
The R0 can be calculated through the following equation: 
 
R0
6
 8.79 10
23
 ΦD  
2n-4J(λ)  Equation 2  
 
ΦD is the quantum yield of the donor, κ is the dipole orientation factor (typically κ
2
 = 2/3), n is the 
refractive index of the medium (1.33 in water) and J (in units of M
-1
cm
3
) is the spectral overlap integral 
that expresses the degree of spectral overlap between the donor emission and the acceptor 
absorption. This parameter can be determined by: 
 
J (λ) ∫ FD(λ)εA(λ)λ
4 
0
dλ  Equation 3 
 
FD(λ) is the corrected fluorescence intensity of the donor in the wavelength range λ to λ   Δλ with the 
total intensity (area under the curve) normalized to unity. εA(λ) is the extinction coefficient of the 
acceptor at λ, which is typically in units of M
–1
cm
–1
. 
 
The J for FAM and JOE pair is 5.26x10
-13
 M
-1
cm
3
 and the theoretical ΦD is 0.95. Using Equation 3, 
the R0 is 67.3 Å. 
The distance between this pair (r) in T17 structure is of approximately 4 nm, assuming that the 
width between two hybridized oligonucleotides is 2 nm for Watson-Crick hydrogen bonds and 
Hoogsteen hydrogen bonds. Thus, the theoretical E for this distance is approximately 95.8%. 
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Appendix III – Emission spectra of labeled double strand of T17 structure with labeled non-TFO 
 
 
 
Figure A.2 – Emission spectra (λexc = 490 nm) of double helix of T17 structure (1T17 and 2T17_5’FAM) and 
labeled non-TFO in 10 mM Tris-HCl (pH 7.6) and different ionic conditions. 
 
 
Figure A.3 – Excitation spectra (λem = 640 nm) in 10 mM Tris-HCl (pH 7.6) and different concentrations of 
MgCl2 and/or NaCl. 
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Appendix IV – Excitation spectra analysis explanation 
 
 
Figure A.4 – Schematic representation of emission and excitation spectra of A) one fluorophore that does 
not emit at the λexc set; B) two fluorophores that do not interact by FRET; C) two fluorophores that do not interact 
by FRET but where the green fluorophore has a residual emission at the λexc set and the orange fluorophore has 
a significant emission at the λexc set; D) two fluorophores where FRET occurs from the green fluorophore to the 
orange fluorophore. The dashed line indicates the λexc set. Green fluorophore: FAM; Orange fluorophore: JOE. 
 
At the fluorescence monitoring wavelength chosen, JOE is the major responsible for emission. For 
simplification sake, if we consider that FAM had no emission at this wavelength, when only FAM is 
present in solution, no emission in the excitation spectrum would be observed (Figure A.3A), since 
FAM would not emit at 640 nm. 
In the presence of both fluorophores but if energy transfer does not occur only the emission 
originated through JOE excitation would be detected (Figure A.3B). It should be noted that the 
emission intensity is directly proportional to the absorbance of the fluorophore, and thus the excitation 
spectrum of JOE should correspond to its absorption spectrum. This is the reason why the excitation 
spectrum maximum corresponds to JOE’s maximum absorption wavelength. 
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Unfortunately, FAM presents non-negligible emission at 640 nm that can be observed in the 
excitation spectrum when both dyes are present (Figure A.3C). Here, both FAM and JOE excitation 
peaks can be observed at 490 nm and 530 nm, which once more, correspond to their absorption 
maximum. When the process of energy transfer occurs between the two fluorophores (Figure A.3D), 
upon FAM excitation, a percentage of that excitation will be transferred to JOE, which is able to emit 
photons at the monitoring wavelength. Therefore, the excitation spectra will evidence the presence of 
two clear peaks: one more intense at 490 nm, which corresponds to the energy transferred from FAM 
to JOE (plus a smaller contribution of FAM emission at 640 nm); and one at 520 nm which is 
originated in JOE’s absorption. Excitation spectra analysis does not completely overcome the problem 
of direct excitation and emission cross-talk, but it offers an alternative and clearer method to split both 
contributions from the energy transfer one. 
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Appendix V – AuNPs characterization 
 
 
Figure A.5 – Gold nanoparticles. A) TEM image and (B) size histogram. AuNPs average size: 14 nm 
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Appendix VI – AuNPs functionalized with different concentrations of PEG 
 
 
Figure A.6 – Visible spectra of AuNPs functionalized with different concentrations of PEG. Spectra 
represented with red lines reveal a single SPR peak at 520 nm and represent the dispersed AuNPs; and spectra 
represented with blue have two peaks, one at 600 nm denoting aggregation of the AuNPs and the other is slightly 
red-shifted from 520 nm which indicates that the aggregation is not complete. 
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Appendix VII – Determination of dsDNA functionalized onto the AuNPs’ surface 
 
 
 
Figure A.7 – Calibration curve for quantification of 2T17_5’JOE oligonucleotide. 
 
Table A.1 – Intensity measured at 550 nm upon excitation of the samples at 520 nm.  The average and 
standard deviation were determined with the intensity of samples 1 and 2; sample 3 was discarded. 
Sample Intensity at 550 nm (a.u.) Average intensity (a.u.) Concentration (μM) 
1 3.235 
3.130 ± 0.150 0.006 ± 0.001 2 3.026 
3 5.201 
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Appendix VIII – Determination of thiolated oligonucleotides functionalized onto AuNPs’ surface 
 
 
Figure A.8 – Calibration curve for quantification of 1T17_5’thiol_3’FAM oligonucleotide. 
 
Table A.2 – Intensity measured at 520 nm upon excitation of the samples at 490 nm.  The average and 
standard deviation were determined with the intensity of samples 1 to 3. 
Sample Intensity at 520 nm (a.u.) Average intensity (a.u.) Concentration (μM) 
1 137.6 
140.5 ± 3.5 0.706 ± 0.024 2 144.3 
3 139.5 
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Appendix IX – Theoretical calculation of laser intensity to triple strand delivery from AuNPs 
 
In the steady-state regime, the local temperature around a single spherical nanoparticle is 
described by the following equation: 
 
 T (r) 
VNPQ
4 k0r
   Equation 4 
 
where r is the surrounding medium radius from the surface of a nanoparticle, k0 is the thermal 
conductivity of the surrounding medium, and VNP is the NP volume. Q is the heat generation coming 
from light dissipation in the nanoparticle. This value can be calculated assuming that the wavelength 
of the incident light is much longer that the nanoparticle radius. 
 
Q 
CabsI0
VNP
  Equation 5 
 
Cabs is the absorption cross-section at the laser intensity of choice for a nanoparticle with a specific 
radius and I0 is the laser intensity in Wm
-2
. 
 
The radius of the AuNPs is 7x10
-9
 m, which corresponds to a volume (VAuNP) of 1.44x10
-24
 m
3
. The 
k0 in the aqueous solution is 0.58 W(m.K)
 -1
. 
The light wavelength of most lasers used for these applications is 532 nm and this is the 
wavelength used for this calculation. Thus, the Cabs for this laser wavelength and AuNP radius is 
approximately 1.33x10
-16 
m
2
. 
To achieve the Tm of the triplex to duplex of T17 structure (calculated as approximately 40ºC by UV 
melting curve), the ΔT is a 3ºC raise from physiological temperature (37ºC) at a distance of circa 8.3 
nm from the surface of the AuNP. This value was calculated according to the values shown in Table 
A.3: 
 
r = 0.285 + 0.182 + (6 x 0.154) + (21 x 0.33) = 8.32 nm 
 
Table A.3 – Bond lengths used to calculate the distance from the surface of the AuNPs to the end of the 
triple helix in the T17 structure. The length between nucleic acid bases is 0.33 nm. 
 Chemical bond length (nm) 
C – C 0.154 
C – S 0.182 
S – Au 0.285 
 
When a laser of 3x10
5
 W/cm
2
 is used, the following theoretical increase in the temperature is verified: 
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Figure A.9 – Temperature increase according to the distance from the AuNP surface when a 532 nm laser 
wavelength with an intensity of 3x10
5
 W/cm
2
 is used. The temperature raise at a distance of 8.3 nm is 
approximately 4.5ºC although only a raise of 3ºC was needed, which gives a margin of error. 
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Appendix X – Inhibition of in vitro transcription: electrophoretic results 
 
 
Figure A.10 – 2% agarose gel of inhibition of in vitro transcription without pre-hybridization of DNA 
template and inhibitory oligonucleotides (T7 antisense and 3T17_T7). Lanes: 1- Negative control (without T7 
RNA polymerase); 2- Positive control (regular in vitro transcription); 3- 0.2 μM T7 antisense; 4- 0.4 μM T7 
antisense; 5- 0.6 μM T7 antisense; 6- 0.8 μM T7 antisense; 7- 1 μM T7 antisense; 8- 0.2 μM 3T17_T7; 9- 0.4 μM 
3T17_T7; 10- 0.6 μM 3T17_T7; 11- 0.8 μM 3T17_T7; 12- 1 μM 3T17_T7. Electrophoretic conditions: 6 V/cm, 90 
min, GelRed incorporation. 
 
 
Figure A.11 – 2% agarose gel of inhibition of in vitro transcription with pre-hybridization of DNA template 
and inhibitory oligonucleotides (T7 antisense and 3T17_T7). Lanes: 1- Negative control (without T7 RNA 
polymerase); 2- Positive control (regular in vitro transcription); 3- 0.2 μM T7 antisense; 4- 0.4 μM T7 antisense; 5- 
0.6 μM T7 antisense; 6- 0.8 μM T7 antisense; 7- 1 μM T7 antisense; 8- oligonucleotide control (1 μM T7 
antisense) without transcription; 9- 0.2 μM 3T17_T7; 10- 0.4 μM 3T17_T7; 11- 0.6 μM 3T17_T7; 12- 0.8 μM 
3T17_T7; 13- 1 μM 3T17_T7; 14- oligonucleotide control (1 μM 3T17_T7) without transcription. Electrophoretic 
conditions: 6 V/cm, 90 min, GelRed incorporation. 
 
 
 
